Headway Startup Diligence Report
Proceed only to confirmatory diligence. Headline funding and market need are attractive, but a transaction thesis requires proof of ARR durability, payer economics, claim-denial performance, provider retention, compliance controls, patient outcomes and cap-table terms.
Headway Startup Diligence Report
Headway is a credible active private unicorn: CB Insights lists it as a U.S. healthcare unicorn, and company plus independent sources corroborate the 2023 Series C and 2024 Series D financing history. Public evidence supports a real insurance-native mental-health access platform, but the investability question remains dominated by private financial quality, payer/provider concentration, claims controls, regulatory/privacy exposure and unit economics.
Revenue, ARR, gross margin, claims economics, cash, debt, burn and retention are not public.
Diligence request: Request audited financials, KPI pack, reimbursement waterfall, provider payout model, cash/debt and cohort retention.
Headway handles health-information, payment and insurance workflows and is expanding into Medicare Advantage/Medicaid.
Diligence request: Obtain HIPAA/security risk assessments, SOC reports, privacy maps, BAAs, incident logs and public-program compliance evidence.
Headline valuations are public, but preferences, investor rights, debt, option pool and liquidation waterfall are private.
Diligence request: Review cap table, financing documents, side letters, debt agreements and valuation bridge.
Public provider counts and claims do not prove active provider supply, quality, geographic density, credentialing status or retention.
Diligence request: Reconcile active vs credentialed providers by state/specialty, credentialing quality, provider churn and satisfaction.
Payer contracts, rates, concentration, renewal terms, audit rights and claims denial/appeal metrics are private.
Diligence request: Review payer contracts, reimbursement rates, concentration, denial rates, audits and renewal schedule.
Credentialing, billing, claims and PHI workflows require robust technical and operational controls not proven publicly.
Diligence request: Review architecture, control testing, claim-denial data, incident logs, roadmap and QA evidence.
Several competitors publicly emphasize insured therapy, provider networks, online therapy or large licensed-provider access.
Diligence request: Run win/loss analysis, payer/provider overlap, pricing benchmarks and independent buyer references.
CAC, payback, conversion, payer sales cycle and provider activation capacity are not public.
Diligence request: Request GTM funnel, CAC/payback, channel attribution, sales productivity and implementation backlog.
Public evidence verifies Headway's unicorn status and recent financings, but core operating financials, cash flow, debt, retention, valuation bridge and cap-table economics are not public.
not publicly verifiable confidence: low
No audited financial statements, revenue, ARR, margin, cash, debt, burn, cohort retention or budget-to-actuals were found in public materials.
| financial area | public status | required private evidence | risk id |
|---|---|---|---|
| Revenue / ARR / bookings | Not disclosed in reviewed sources | Audited revenue, ARR bridge, bookings, deferred revenue and customer-level revenue. | R-001 |
| Gross margin / claims economics | Not disclosed; business model only directionally described | Payer reimbursement, provider payouts, denied claims, appeals, COGS and support costs. | R-001 |
| Cash / debt / burn | Not disclosed | Cash balance, debt schedule, runway, burn and budget-to-actuals. | R-001 |
Expected for a private company, but central to underwriting valuation.
partially verified confidence: medium
CB Insights and funding coverage support public valuation anchors, but projections and valuation support are private.
| event | date | amount or valuation | public evidence | diligence readout |
|---|---|---|---|---|
| Series C / unicorn round | 2023-10-05 / 2023-10-06 | $125M Series C; more than $1B valuation | MobiHealthNews and MedCity reported the Series C, Spark lead and investor participation. | Supports unicorn entry; does not prove common-equity value or operating metrics. |
| CB Insights unicorn listing | 2023-10-05 | $1B listed valuation | CB Insights lists Headway as a U.S. Healthcare & Life Sciences unicorn. | Independent market-database corroboration of private unicorn eligibility. |
| Series D | 2024-07-23 | $100M Series D; $2.3B valuation | PRNewswire and MobiHealthNews reported Spark-led Series D with a $2.3B valuation. | Strong valuation step-up signal; terms and performance support remain private. |
| Secondary-database funding triangulation | 2024-07 | $2.3B valuation; roughly $325.5M total funding estimate | Sacra excerpt triangulates Series D valuation/funding and 70+ insurance-plan partnerships. | Useful cross-check; verify against stock-purchase agreements, cap table and investor closing documents. |
No financing documents, preferences or cap table were public.
Includes both company-published and independent funding sources.
Chart uses public headline valuations only.
partially verified confidence: medium
Investor names and funding rounds are public; ownership, preferences, debt, option pool and liquidation waterfall are not.
| item | public evidence | diligence gap |
|---|---|---|
| Named investors | CB Insights lists Accel, Thrive Capital and Andreessen Horowitz; the Series D announcement adds Spark, Forerunner, GV and HCSC context. | Ownership percentages, class rights, board rights and side letters. |
| Financing terms | Funding amounts and headline valuations are public. | Liquidation preferences, anti-dilution, debt, warrants and option-pool refresh. |
| Private status | Active public site, CB unicorn listing and 2024 private funding coverage were found. | Corporate good standing, current shareholder registry and any undisclosed corporate actions. |
Investor quality is not a substitute for term-sheet and cap-table review.
Headway publicly advertises an insurance-covered mental-health marketplace and provider back-office workflow. Product-market evidence is meaningful, but module economics, claims accuracy, quality controls and outcomes require private validation.
verified confidence: medium
Public materials describe patient search/booking, provider credentialing/billing/claims support and payer access workflows.
| product area | public evidence | diligence question |
|---|---|---|
| Patient search and booking | Homepage says patients can find a therapist who takes insurance and may pay as low as $0/session. | Validate availability, conversion, appointment time, copay distribution and patient outcomes. |
| Provider insurance administration | Provider materials advertise credentialing, automated claims and membership-free practice support. | Validate credentialing speed, claims accuracy, denial rates and provider retention. |
| Payer network access | Series D release says Headway was in-network with more than 40 commercial health plans across 50 states and D.C. | Validate payer contracts, rates, utilization and network adequacy obligations. |
| Public-program expansion tooling | Series D proceeds are intended to build tools for Medicare/Medicaid credentialing and compliance. | Validate roadmap, launch status, controls and economics. |
Public product breadth does not establish adoption or economics.
Conceptual diagram from public descriptions, not technical architecture documentation.
partially verified confidence: medium
Patient affordability and a provider-friendly platform are public themes, but exact payer reimbursement economics and product margins are private.
| economics area | public signal | private evidence required |
|---|---|---|
| Patient affordability | Homepage advertises paying as low as $0/session with insurance. | Copay distribution by plan, patient cancellation/no-show economics and conversion by price band. |
| Provider pricing | Provider page positioning emphasizes membership-free insurance enablement. | Provider payout rates, payment timing, deductions, churn and satisfaction. |
| Health-plan take rate | MedCity reports Headway operates by taking a small percentage from the premium paid by health plans. | Contracted rates, take rate, claims yield, denial/appeal rates and gross margin. |
Pricing and reimbursement economics should be modeled by payer, state and provider type.
Headway serves a three-sided network of patients, providers and payers. Public materials support broad constituency claims, but customer concentration, revenue by payer, churn and contract status remain non-public.
partially verified confidence: medium
Public sources identify patient, provider and payer constituencies rather than disclosing top customers by revenue or application.
| segment | public evidence | diligence readout |
|---|---|---|
| Patients | Headway homepage targets patients seeking insured therapists and psychiatrists. | Demand-side presence is visible; utilization and outcomes are private. |
| Providers | Headway provider materials and PRNewswire describe clinicians using the platform to run private practices. | Provider supply is central; active-vs-credentialed and retention need validation. |
| Payers / health plans | PRNewswire reports more than 40 commercial health plans and planned MA/Medicaid expansion. | Payer relationships are material; economics and concentration are private. |
| Primary-care referring clinicians | 2025 PRNewswire announcement cites partnerships with medical organizations representing 15,000+ clinicians and 10,000+ referrals. | Referral-channel traction is visible, but conversion, appointment completion and contract obligations are private. |
Constituent scale does not equal revenue by customer.
Demand and referral counts are public anchors; conversion, visit completion and reimbursement remain private.
partially verified confidence: medium
Public materials reference commercial health plans, Medicare Advantage/Medicaid expansion and named investors, but not relationship economics.
| relationship type | public signal | private validation needed |
|---|---|---|
| Commercial health plans | More than 40 commercial health plans across 50 states and D.C. reported by PRNewswire. | Contract inventory, rates, concentration, renewal/termination and audit rights. |
| Medicare Advantage and Medicaid | Series D release described planned expansion and certain Medicare Advantage work already underway. | State/plan launch status, compliance obligations, provider participation and claim performance. |
| Investors / board | Spark led Series D; Will Reed of Spark is described as a board member. | Board rights, observer rights, reserved matters and governance structure. |
| Named commercial payer examples | Behavioral Health Business excerpt names Aetna, Anthem BCBS, UnitedHealthcare, Cigna, Oscar and Oxford as payer examples. | Revenue concentration, contracted rates, audit rights, termination rights and renewals by payer. |
| Primary-care medical organizations | Headway says medical-organization partnerships cover 15,000+ clinicians and have produced 10,000+ referrals. | Partner contracts, referral attribution, conversion, appointment completion and outcomes. |
| Insurance-plan partnership count | Sacra secondary profile reports 70+ insurance-plan partnerships. | Primary contract inventory and current active/inactive plan reconciliation. |
Strategic relationships are public signals only; contracts are required for diligence.
not publicly verifiable confidence: low
No public revenue-by-customer, churn, supplier-dependency or severed-relationship schedule was found.
| area | public status | why it matters |
|---|---|---|
| Top payer/customer concentration | Not public | Payer concentration could create price-reset, termination or audit exposure. |
| Retention / churn / utilization | Not public | Network-marketplace value depends on repeat patient utilization and provider/payer retention. |
| Supplier and technology dependencies | Not public | Claims, scheduling, identity, hosting or payment vendors could affect reliability and compliance. |
| Payer and referral-channel economics | Named payer examples and referral counts are public; revenue concentration and economics are not. | Named relationships and referral volume can still hide concentration, unfavorable rates, leakage or weak conversion. |
Request schedules directly from management.
Headway competes in a crowded mental-health access, provider enablement and virtual-care landscape. Its insurance-native workflow and network scale are plausible differentiators but require win/loss, pricing and buyer-reference validation.
partially verified confidence: medium
Official competitor pages show overlapping insured-therapy, provider-network, virtual-therapy and marketplace positioning.
| company | public positioning | headway implication |
|---|---|---|
| Alma | Homepage frames Alma around simplifying access to therapy and has provider insurance-program materials. | Direct adjacency in insured therapy access and provider enablement. |
| Grow Therapy | Homepage title advertises therapy near you and online therapy that takes insurance. | Direct patient-acquisition and insured-care competition. |
| Rula | Homepage and navigation emphasize mental-health experts, insurance coverage, health-plan partnerships and Medicare/Medicaid provider signup. | Overlaps in patient, provider and payer channels. |
| Talkspace | Homepage advertises online therapy, medication management, insurance coverage and 1M+ users. | Broader virtual-care brand competes for patients and health-plan relationships. |
| BetterHelp | Homepage calls BetterHelp the world's largest therapy service with licensed therapists. | Large direct-to-consumer substitute may pressure patient acquisition and brand awareness. |
This table is positioning-based; it is not market-share or outcome benchmarking.
| hypothesis | supporting public signal | validation needed |
|---|---|---|
| Insurance-native provider workflow | Headway markets credentialing, billing and claims support and says it helps clinicians accept insurance. | Provider interviews, onboarding metrics, claim-denial rates and time-to-payment. |
| Payer/public-program access | Series D release emphasizes commercial health plans plus Medicare Advantage and Medicaid expansion. | Payer contracts, rates, launch status and compliance readiness. |
| Provider network scale | Public sources cite 34,000 providers in 2024 and company provider-page claims of 70,000+ credentialed providers in later reviewed materials. | Active provider roster, geography/specialty density and provider retention. |
Differentiation claims require customer, provider and payer references.
Scores are analyst-coded from public positioning and should be validated with market research.
Does not measure actual payer penetration.
verified confidence: high
Public-health sources support strong need for mental-health access, and HHS OIG highlights Medicare/Medicaid access shortages.
| signal | public evidence | diligence implication |
|---|---|---|
| Mental-health need | NIMH estimated 59.3M U.S. adults with any mental illness in 2022. | Large need supports category demand but not Headway conversion or profitability. |
| Medicare/Medicaid provider access | HHS OIG reported few behavioral-health providers in selected counties actively served Medicare and Medicaid enrollees. | Public-program expansion addresses a real access gap but increases compliance complexity. |
| Covered lives for expansion | Headway's Series D release says Medicare Advantage and Medicaid cover more than 100M people. | Large nominal TAM; Headway needs plan-by-plan penetration and reimbursement validation. |
Demand and access gaps are necessary but not sufficient for durable unit economics.
Visible GTM channels include patient search/SEO, provider acquisition and payer partnerships. Public evidence does not disclose CAC, conversion, sales productivity, payback or implementation capacity.
partially verified confidence: medium
Headway's public GTM combines patient-facing provider search, provider enablement and payer/public-program network expansion.
| channel | public evidence | metric to validate |
|---|---|---|
| Patient search / SEO | Homepage exposes therapist and psychiatrist search with city/state pages. | Traffic, conversion, appointment completion, repeat utilization and CAC. |
| Provider acquisition | Provider materials market taking insurance with credentialing, claims and practice support. | Lead-to-active-provider conversion, credentialing time, active sessions and provider churn. |
| Payer partnerships | PRNewswire cites commercial health plans and public-program expansion. | Payer pipeline, contract win rate, rates, launch time and concentration. |
| Primary-care referrals / integrated care | PRNewswire reports nationwide integrated-care launch, 15,000+ referring clinicians, 10,000+ referrals and appointment availability within 48 hours. | Referral-to-booking conversion, appointment completion, patient outcome, partner economics and retention. |
GTM diligence should analyze all three sides of the network by market.
Funnel is conceptual, not a true conversion report.
Do not add the bars; they represent different populations.
not publicly verifiable confidence: low
Sales productivity, marketing budget sufficiency and implementation capacity are not public.
| metric | public status | request |
|---|---|---|
| CAC / payback | Not public | CAC by patient/provider/payer channel, payback period and marketing spend by cohort. |
| Payer sales cycle | Not public | Pipeline, stage conversion, cycle length, win/loss and implementation time. |
| Provider activation capacity | Not public | Onboarding capacity, credentialing backlog, activation rate and support staffing. |
Marketing budget adequacy cannot be assessed without operating metrics.
Public R&D signals include platform development, Medicare/Medicaid credentialing tools and insurance-native workflow expansion. Diligence should validate technical architecture, security controls, data rights, product velocity and claims-processing accuracy.
partially verified confidence: medium
Public materials describe product-development priorities but not the engineering organization, roadmap ownership or release metrics.
| roadmap area | public signal | validation needed |
|---|---|---|
| Medicare/Medicaid credentialing | Series D release says funds will help build tools to accelerate Medicare and Medicaid credentialing timelines and compliance requirements. | Roadmap, releases, adoption, compliance testing and state-by-state launch status. |
| Provider practice operations | Funding announcement emphasizes simplifying private-practice operations for clinicians. | Provider workflow analytics, support volume, NPS and claim outcomes. |
| Insurance-native EHR / workflow expansion | A Headway blog title reviewed in this workflow described expanding a free insurance-native EHR. | Product scope, adoption, integration, compliance and monetization plan. |
Roadmap evidence is directional and company-published.
Requires SOC/security and architecture artifacts.
partially verified confidence: medium
HIPAA and privacy materials show regulated data-flow obligations; public sources do not prove control operating effectiveness.
| control area | public evidence | artifact request |
|---|---|---|
| PHI treatment/payment/operations | HIPAA Notice states health information may be used for treatment, payment and healthcare operations. | HIPAA risk analysis, policies, audit logs, BAAs and control testing. |
| Claims and billing | Product pages and news coverage reference billing, automated claims and claims submission. | Claim-denial rate, appeals, audit results, reimbursement controls and payer audit history. |
| Business customer data | California privacy notice covers business customers including providers and plan representatives. | Data map, retention schedule, state privacy analysis and vendor subprocessors. |
Public notices do not prove controls are designed or operating effectively.
Public sources identify Andrew Adams as founder/CEO and Will Reed of Spark as a board member, but full leadership depth, headcount, compensation, attrition and governance rights are not public.
partially verified confidence: medium
Public leadership evidence is limited to selected named roles in funding articles and company statements.
| person or body | public role | diligence need |
|---|---|---|
| Andrew Adams | Founder & CEO, quoted in Series C and Series D coverage. | Management interview, references, performance review and equity/compensation terms. |
| Will Reed / Spark Capital | Spark general partner and Headway board member according to Series D/MobiHealth coverage. | Board rights, observer rights, reserved matters and investor governance. |
| Full management team and board | Not fully disclosed in reviewed public materials. | Full org chart, executive bios, board list and succession plan. |
Only selected roles were verified publicly.
Not a full org chart.
not publicly verifiable confidence: low
Employee headcount, hiring plan, attrition, compensation, stock plans and employee-relations issues were not publicly verifiable.
| area | public status | risk |
|---|---|---|
| Employee headcount by function/location | Not public in reviewed sources | Support, engineering, compliance and payer operations capacity cannot be assessed. |
| Provider network count | Publicly reported as 34,000 providers in 2024 and 70,000+ credentialed providers on later provider materials. | Providers are supply-side network participants, not employees; active status and retention require reconciliation. |
| Compensation, equity and employee relations | Not public | Retention, incentive alignment and undisclosed employee matters may affect scaling. |
Request HRIS export and provider-network reconciliation separately.
Headway operates in a regulated health-care and insurance workflow context. Public HIPAA and California privacy notices confirm privacy obligations, but litigation, regulatory inquiries, payer/provider contract exposure, insurance coverage and IP schedules require counsel-led diligence.
not publicly verifiable confidence: low
No comprehensive public legal docket search was completed; active public materials and funding coverage did not reveal an exit event.
| screen area | public evidence | readout |
|---|---|---|
| Active public site | Headway homepage remained accessible through r.jina.ai and contained active product/legal links. | Supports active operations; not a corporate-status certificate. |
| Private-unicorn list | CB Insights still includes Headway in the unicorn list row reviewed. | Supports private-unicorn eligibility; not a securities-law determination. |
| Exit/shutdown evidence | No IPO, acquisition or shutdown evidence appeared in the targeted public search performed; recent funding/active pages were found instead. | No stop signal found, but counsel should confirm through corporate records and company representations. |
This is not a comprehensive docket, SEC, state corporate-record or M&A database search.
partially verified confidence: medium
HIPAA and state privacy notices create a clear regulated data surface; environmental exposure appears limited by software/services operations but workplace safety was not public.
| surface | public evidence | diligence implication |
|---|---|---|
| HIPAA / PHI | HIPAA Notice describes Headway-affiliated professional entities, business-associate role and health-information uses. | Review BAAs, HIPAA policies, risk assessment, breach log and control testing. |
| State privacy / business customers | California privacy notice applies to providers and health-plan representatives as business customers. | Review state privacy mapping, data retention, opt-out/rights workflows and vendor subprocessors. |
| Medicare Advantage / Medicaid | Series D announcement says Headway planned expansion into Medicare Advantage and Medicaid. | Review licensing, credentialing, network adequacy, claims, fraud/waste/abuse and audit controls. |
Counsel should assess obligations by state, payer and provider type.
Risk ratings are public-diligence judgments, not management assertions.
not publicly verifiable confidence: low
Material patents, trademarks, licenses, open-source exposure, insurance coverage and payer/provider contract terms were not publicly verifiable.
| area | public status | requested artifact |
|---|---|---|
| Material contracts | Payer/provider relationship categories are public; terms are not. | Payer contracts, provider agreements, vendor contracts and termination/renewal schedule. |
| IP and data rights | No patent, trademark, copyright, open-source or data-rights schedule was public in reviewed sources. | IP schedule, open-source inventory, assignment agreements and data-rights analysis. |
| Insurance coverage | Not public | Cyber, E&O, D&O, professional liability and claims history. |
Material-contract review is essential because Headway's model is contract-heavy.
| ID | Claim | Status | Sources |
|---|---|---|---|
| EC-001 | CB Insights lists Headway as a $1B U.S. Healthcare & Life Sciences unicorn that joined on 2023-10-05. | verified high | SRC-001 |
| EC-002 | Headway announced a $100M Series D at a $2.3B valuation in July 2024. | verified high | SRC-005 |
| EC-003 | Independent health-tech news coverage corroborates Headway's $100M Series D and $2.3B valuation. | verified high | SRC-006 |
| EC-004 | Headway reached unicorn status through a $125M Series C round in 2023. | verified high | SRC-007SRC-008 |
| EC-005 | Headway publicly markets insured therapist and psychiatrist search for patients. | verified medium | SRC-002 |
| EC-006 | Headway public provider materials advertise insurance enablement, claims automation and large provider-network scale. | partially verified medium | SRC-003 |
| EC-007 | Headway company materials frame the mission around insurance access and therapist insurance acceptance gaps. | partially verified medium | SRC-004 |
| EC-008 | Headway reported significant provider and payer network scale in its Series D announcement. | verified medium | SRC-005 |
| EC-009 | U.S. mental-health demand is large, with NIMH estimating 59.3M adults with any mental illness in 2022. | verified high | SRC-009 |
| EC-010 | HHS OIG found behavioral-health provider access problems for Medicare and Medicaid enrollees. | verified high | SRC-010 |
| EC-011 | Public competitor pages show crowded adjacent positioning in therapy access, insurance coverage and provider networks. | verified medium | SRC-011SRC-012SRC-013SRC-014SRC-015 |
| EC-012 | Independent coverage describes Headway as connecting patients, providers and insurance companies with booking, billing and back-end tasks. | verified medium | SRC-006SRC-007 |
| EC-013 | Headway's public GTM includes patient search, provider acquisition and payer expansion. | partially verified medium | SRC-002SRC-003SRC-005 |
| EC-014 | Public sources indicate active product development around private-practice operations and public-program credentialing. | partially verified medium | SRC-005SRC-018 |
| EC-015 | Headway's HIPAA Notice describes regulated health-information use and disclosure obligations. | verified high | SRC-016 |
| EC-016 | Headway's California business privacy notice covers providers and health-plan representatives. | verified high | SRC-017 |
| EC-017 | Headway's operating financials are not publicly verifiable from the reviewed sources. | not publicly verifiable high | SRC-001SRC-005SRC-006SRC-007SRC-008 |
| EC-018 | Customer concentration, revenue by customer and churn are not publicly verifiable from reviewed sources. | not publicly verifiable high | SRC-002SRC-005SRC-006 |
| EC-019 | Legal docket, IP, contracts and insurance coverage are not publicly verifiable from reviewed materials. | not publicly verifiable medium | SRC-002SRC-016SRC-017 |
| EC-020 | No public IPO, acquisition or shutdown stop signal was found in the targeted public screen performed. | partially verified medium | SRC-001SRC-002SRC-005 |
| EC-021 | Public sources identify Andrew Adams as founder/CEO and Will Reed of Spark as a board member. | verified medium | SRC-005SRC-006SRC-008 |
| EC-022 | Employee headcount, attrition, compensation and full organization chart are not publicly verifiable from reviewed sources. | not publicly verifiable high | SRC-005SRC-006SRC-008 |
| EC-023 | MedCity reported that Headway is free for patients and providers and earns by taking a small percentage from health-plan premiums. | partially verified medium | SRC-008 |
| EC-024 | Headway's Medicare Advantage and Medicaid expansion is material and compliance-heavy. | verified high | SRC-005SRC-010 |
| EC-025 | Behavioral Health Business reported payer-partner examples and Headway's payer-commission model around the 2023 Series C. | partially verified medium | SRC-019 |
| EC-026 | Headway announced a nationwide primary-care referral solution with 50,000 insurance-accepting providers and more than 10,000 referrals. | verified medium | SRC-020 |
| EC-027 | Sacra provides secondary-database triangulation of Headway's $2.3B 2024 valuation, funding scale and insurance-plan partnership count. | partially verified medium | SRC-021 |
This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.